Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad) Buy RVMD Stock  Free RVMD Stock Alerts

Revolution Medicines (RVMD) Financials

Revolution Medicines logo
$39.98 +0.90 (+2.30%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$38.40 -1.58 (-3.95%)
As of 05/30/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Revolution Medicines

Annual Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 -600 -436 -249 -187 -110 -62 -49
Consolidated Net Income / (Loss)		 -600 -436 -249 -187 -108 -48 -42
Net Income / (Loss) Continuing Operations		 -600 -436 -249 -187 -108 -48 -42
Total Pre-Tax Income 		-601 -440 -249 -187 -109 -52 -42
Total Operating Income		 -690 -487 -258 -188 -111 -54 -40
Total Gross Profit		 0.00 12 35 29 43 50 20
Total Revenue		 0.00 12 35 29 43 50 20
Operating Revenue		 0.00 12 35 29 43 50 20
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 690 499 294 217 154 104 60
Selling, General & Admin Expense		 97 76 41 30 21 12 9.41
Research & Development Expense		 592 423 253 187 132 92 51
Total Other Income / (Expense), net		 89 47 9.15 0.92 2.17 2.08 -1.46
Interest & Investment Income		 87 47 9.15 0.93 2.24 2.19 0.78
Other Income / (Expense), net		 -2.53 -0.19 0.00 -0.01 - - -2.12
Income Tax Expense		 -0.75 -3.52 -0.42 0.00 -0.37 -4.37 0.00
Basic Earnings per Share		 ($3.58) ($3.86) ($3.08) ($2.57) ($2.01) ($22.33) ($21.24)
Weighted Average Basic Shares Outstanding		 167.74M 113.15M 80.63M 72.81M 54.87M 2.77M 2.30M
Diluted Earnings per Share		 ($3.58) ($3.86) ($3.08) ($2.57) ($2.01) ($22.33) ($21.24)
Weighted Average Diluted Shares Outstanding		 167.74M 113.15M 80.63M 72.81M 54.87M 2.77M 2.30M
Weighted Average Basic & Diluted Shares Outstanding		 185.91M 164.69M 90.49M 72.81M 54.87M 2.77M 2.30M

Quarterly Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -213 -195 -156 -133 -116 -162 -108 -98 -68 -53 -73
Consolidated Net Income / (Loss)		 -213 -195 -156 -133 -116 -162 -108 -98 -68 -53 -73
Net Income / (Loss) Continuing Operations		 -213 -195 -156 -133 -116 -162 -108 -98 -68 -53 -73
Total Pre-Tax Income 		-213 -195 -156 -133 -116 -161 -112 -98 -68 -53 -74
Total Operating Income		 -241 -216 -176 -157 -141 -180 -123 -109 -75 -58 -77
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.74 0.00 3.82 7.01 14 3.36
Total Revenue		 0.00 - 0.00 0.00 0.00 0.74 0.00 3.82 7.01 14 3.36
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 241 216 176 157 141 181 123 113 82 71 80
Selling, General & Admin Expense		 35 29 24 22 23 32 16 15 13 9.74 10
Research & Development Expense		 206 188 152 135 118 148 108 98 69 62 69
Total Other Income / (Expense), net		 27 21 19 23 25 19 11 10 7.06 4.51 2.91
Interest & Investment Income		 25 21 20 21 24 19 11 10 7.06 4.51 2.91
Other Income / (Expense), net		 2.43 -5.83 0.28 1.92 1.10 -0.19 0.00 0.00 0.00 - -
Basic Earnings per Share		 ($1.13) ($1.13) ($0.94) ($0.81) ($0.70) ($1.23) ($0.99) ($0.92) ($0.72) ($0.57) ($0.87)
Weighted Average Basic Shares Outstanding		 188.15M 167.74M 166.84M 165.14M 164.73M 113.15M 109.23M 106.88M 94.83M 80.63M 84.69M
Diluted Earnings per Share		 ($1.13) ($1.13) ($0.94) ($0.81) ($0.70) ($1.23) ($0.99) ($0.92) ($0.72) ($0.57) ($0.87)
Weighted Average Diluted Shares Outstanding		 188.15M 167.74M 166.84M 165.14M 164.73M 113.15M 109.23M 106.88M 94.83M 80.63M 84.69M
Weighted Average Basic & Diluted Shares Outstanding		 186.27M 185.91M 168.22M 167.04M 164.99M 164.69M 109.56M - 109.17M 90.49M 88.79M

Annual Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 -152 536 53 4.88 88 -53 61
Net Cash From Operating Activities		 -557 -351 -224 -147 -100 -50 1.21
Net Cash From Continuing Operating Activities		 -557 -356 -224 -147 -100 -50 1.21
Net Income / (Loss) Continuing Operations		 -600 -436 -249 -187 -108 -48 -42
Consolidated Net Income / (Loss)		 -600 -436 -249 -187 -108 -48 -42
Depreciation Expense		 6.56 - 3.97 3.08 2.61 2.27 1.57
Amortization Expense		 -39 -18 2.61 7.26 4.90 0.62 0.20
Non-Cash Adjustments To Reconcile Net Income		 75 62 31 21 8.89 3.98 3.18
Changes in Operating Assets and Liabilities, net		 0.65 37 -13 8.72 -8.30 -8.83 38
Net Cash From Investing Activities		 -554 -343 -24 -142 -234 -102 -1.34
Net Cash From Continuing Investing Activities		 -554 -343 -24 -142 -234 -102 -1.34
Purchase of Property, Plant & Equipment		 -10 -7.73 -11 -6.53 -2.93 -2.59 -1.50
Purchase of Investments		 -2,137 -1,059 -613 -671 -544 -172 0.00
Sale and/or Maturity of Investments		 1,593 724 599 536 313 67 0.00
Net Cash From Financing Activities		 959 1,229 301 294 423 99 61
Net Cash From Continuing Financing Activities		 959 1,229 301 294 423 99 61
Issuance of Common Equity		 959 392 301 295 423 0.28 0.42
Other Financing Activities, net		 0.28 837 0.04 -0.42 0.00 -1.65 0.13

Quarterly Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -210 343 -75 -13 -408 338 -22 -46 266 -18 73
Net Cash From Operating Activities		 -194 -138 -130 -128 -161 -121 -100 -67 -62 -62 -52
Net Cash From Continuing Operating Activities		 -194 -138 -130 -128 -161 -126 -100 -67 -62 -62 -52
Net Income / (Loss) Continuing Operations		 -213 -195 -156 -133 -116 -162 -108 -98 -68 -57 -73
Consolidated Net Income / (Loss)		 -213 -195 -156 -133 -116 -162 -108 -98 -68 -57 -73
Depreciation Expense		 1.69 1.74 1.64 1.64 1.54 - 1.27 1.22 1.21 1.15 0.99
Amortization Expense		 -7.79 -7.17 -8.36 -9.75 -14 -7.12 -4.27 -4.30 -2.25 -1.14 0.28
Non-Cash Adjustments To Reconcile Net Income		 23 19 22 18 15 26 14 13 9.70 8.32 8.14
Changes in Operating Assets and Liabilities, net		 2.44 42 10 -4.74 -47 21 -2.73 21 -2.95 -14 12
Net Cash From Investing Activities		 -16 -393 -21 108 -248 -380 77 -44 4.00 -7.10 -123
Net Cash From Continuing Investing Activities		 -16 -393 -21 108 -248 -380 77 -44 4.00 -7.10 -123
Purchase of Property, Plant & Equipment		 -3.27 -1.22 -3.52 -2.40 -3.17 -2.32 -2.54 -1.12 -1.76 -2.88 -3.53
Purchase of Investments		 -510 -695 -365 -375 -702 -520 -170 -176 -193 -160 -213
Sale and/or Maturity of Investments		 497 304 347 485 457 142 250 134 199 156 93
Net Cash From Financing Activities		 0.87 874 77 7.50 0.81 839 1.01 65 324 51 248
Net Cash From Continuing Financing Activities		 0.87 874 77 7.50 0.81 839 1.01 65 324 51 248
Issuance of Common Equity		 0.89 874 77 7.50 0.81 2.55 1.01 65 324 51 248
Other Financing Activities, net		 -0.02 - - - - - - - - - -

Annual Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 2,558 2,062 812 738 567 221
Total Current Assets		 2,328 1,879 660 590 454 134
Cash & Equivalents		 543 696 161 108 104 17
Short-Term Investments		 1,746 1,157 484 469 336 106
Accounts Receivable		 0.00 1.25 4.67 5.93 6.39 8.74
Prepaid Expenses		 38 25 11 6.79 6.99 2.49
Plant, Property, & Equipment, net		 24 23 19 12 8.90 7.15
Total Noncurrent Assets		 206 160 133 137 104 79
Goodwill		 15 15 15 15 15 15
Intangible Assets		 57 58 59 60 61 62
Other Noncurrent Operating Assets		 135 87 60 62 29 2.78
Total Liabilities & Shareholders' Equity		 2,558 2,062 812 738 567 221
Total Liabilities		 293 236 127 135 93 68
Total Current Liabilities		 164 144 62 60 47 43
Accounts Payable		 54 62 21 14 13 11
Accrued Expenses		 97 75 29 28 19 15
Other Current Liabilities		 13 7.37 6.77 6.21 3.67 0.00
Total Noncurrent Liabilities		 129 92 65 75 46 25
Noncurrent Deferred & Payable Income Tax Liabilities		 2.35 3.12 7.03 7.44 7.44 7.82
Other Noncurrent Operating Liabilities		 127 89 58 61 30 0.66
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,265 1,826 685 603 475 -153
Total Preferred & Common Equity		 2,265 1,826 685 603 475 -153
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,265 1,826 685 603 475 -153
Common Stock		 4,002 2,963 1,388 1,056 740 4.74
Retained Earnings		 -1,738 -1,138 -701 -453 -266 -157
Accumulated Other Comprehensive Income / (Loss)		 1.32 0.54 -1.78 -0.38 0.12 0.07

Quarterly Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 9/30/2022
Total Assets		 2,365 1,763 1,808 1,908 984 1,074 826
Total Current Assets		 2,135 1,579 1,625 1,729 824 922 675
Cash & Equivalents		 334 201 276 288 358 380 179
Short-Term Investments		 1,769 1,348 1,315 1,415 455 529 476
Accounts Receivable		 0.00 0.00 0.00 0.00 0.31 2.51 4.94
Prepaid Expenses		 32 30 34 26 11 10 15
Plant, Property, & Equipment, net		 27 25 25 24 20 20 18
Total Noncurrent Assets		 204 159 158 155 139 132 133
Goodwill		 15 15 15 15 15 15 15
Intangible Assets		 56 57 57 57 58 58 59
Other Noncurrent Operating Assets		 133 88 87 83 67 59 59
Total Liabilities & Shareholders' Equity		 2,365 1,763 1,808 1,908 984 1,074 826
Total Liabilities		 287 197 190 183 147 143 144
Total Current Liabilities		 159 111 105 94 86 78 73
Accounts Payable		 48 24 29 32 30 30 24
Accrued Expenses		 98 78 68 53 50 43 32
Other Current Liabilities		 13 8.40 8.33 8.17 5.76 5.72 7.02
Total Noncurrent Liabilities		 129 86 84 89 61 65 71
Noncurrent Deferred & Payable Income Tax Liabilities		 2.35 3.12 3.12 3.12 3.16 7.03 7.15
Other Noncurrent Operating Liabilities		 126 83 81 86 58 58 59
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,078 1,566 1,619 1,725 837 931 681
Total Preferred & Common Equity		 2,078 1,566 1,619 1,725 837 931 681
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,078 1,566 1,619 1,725 837 931 681
Common Stock		 4,028 3,106 3,008 2,980 1,815 1,800 1,329
Retained Earnings		 -1,951 -1,543 -1,387 -1,254 -976 -868 -645
Accumulated Other Comprehensive Income / (Loss)		 1.71 3.81 -1.86 -1.20 -0.87 -1.25 -2.42

Annual Metrics And Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 -100.00% -67.27% 20.38% -31.62% -14.10% 148.16% 0.00%
EBITDA Growth		 -43.44% -100.76% -41.66% -72.19% -101.42% -25.91% 0.00%
EBIT Growth		 -42.00% -88.70% -37.37% -69.85% -104.54% -27.49% 0.00%
NOPAT Growth		 -41.53% -88.63% -37.38% -69.84% -104.54% -34.20% 0.00%
Net Income Growth		 -37.52% -75.46% -32.93% -72.98% -126.92% -14.06% 0.00%
EPS Growth		 7.25% -25.32% -19.84% -27.86% 91.00% -5.13% 0.00%
Operating Cash Flow Growth		 -59.01% -56.23% -52.47% -47.09% -101.68% -4,190.35% 0.00%
Free Cash Flow Firm Growth		 -77.11% -40.15% -58.73% -50.88% -20.67% 0.00% 0.00%
Invested Capital Growth		 9.96% -166.50% 57.74% -24.82% 13.96% 0.00% 0.00%
Revenue Q/Q Growth		 -100.00% -52.98% 13.95% 2.47% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.09% -35.88% -3.11% -11.40% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -6.46% -33.61% -1.84% -11.14% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -5.56% -33.56% -1.84% -11.13% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -5.83% -33.14% -0.10% -10.95% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 2.72% -20.63% 4.64% -14.73% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -3.28% -20.14% -11.16% -10.70% -15.44% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -7.90% -8.23% -12.12% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -243.23% -210.30% 52.41% -13.66% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -4,363.65% -711.42% -604.55% -240.06% -102.37% -201.77%
Operating Margin		 0.00% -4,207.12% -730.01% -639.70% -257.54% -108.15% -200.00%
EBIT Margin		 0.00% -4,208.75% -730.01% -639.74% -257.54% -108.15% -210.51%
Profit (Net Income) Margin		 0.00% -3,768.28% -702.95% -636.58% -251.63% -95.25% -207.24%
Tax Burden Percent		 99.87% 99.20% 99.83% 100.00% 99.66% 91.60% 100.00%
Interest Burden Percent		 86.82% 90.26% 96.46% 99.51% 98.04% 96.15% 98.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -5,058.28% -549.87% -442.75% -243.24% -254.45% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -5,050.65% -538.76% -431.85% -232.36% -238.52% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 5,023.53% 511.25% 408.02% 208.76% 191.96% 0.00%
Return on Equity (ROE)		 -29.33% -34.75% -38.63% -34.74% -34.49% -62.50% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -594.68% -414.42% -256.30% -454.45% 0.00%
Operating Return on Assets (OROA)		 0.00% -33.92% -33.33% -28.81% -28.10% -24.54% 0.00%
Return on Assets (ROA)		 0.00% -30.37% -32.09% -28.66% -27.45% -21.61% 0.00%
Return on Common Equity (ROCE)		 -29.33% -34.75% -38.63% -34.74% -17.71% 62.51% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -26.49% -23.89% -36.30% -31.05% -22.79% 31.24% 0.00%
Net Operating Profit after Tax (NOPAT)		 -483 -341 -181 -132 -77 -38 -28
NOPAT Margin		 0.00% -2,944.99% -511.01% -447.79% -180.28% -75.71% -140.00%
Net Nonoperating Expense Percent (NNEP)		 -5.67% -7.63% -11.11% -10.90% -10.89% -15.93% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -21.31% -18.67% -26.39% - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 653.03% 114.71% 103.61% 49.85% 24.79% 46.67%
R&D to Revenue		 0.00% 3,654.09% 715.30% 636.09% 307.68% 183.36% 253.33%
Operating Expenses to Revenue		 0.00% 4,307.12% 830.01% 739.70% 357.54% 208.15% 300.00%
Earnings before Interest and Taxes (EBIT)		 -692 -487 -258 -188 -111 -54 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -725 -505 -252 -178 -103 -51 -41
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 3.25 1.72 3.09 3.08 5.54 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.35 1.79 3.46 3.51 6.58 0.00 0.00
Price to Revenue (P/Rev)		 0.00 271.36 59.78 63.11 61.14 3.00 7.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 36.53 50.08 64.45 11.16 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 111.34 41.55 43.47 50.89 6.64 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -0.99 -0.95 -0.94 -0.90 -0.80 0.00
Leverage Ratio		 1.13 1.14 1.20 1.21 1.26 1.45 0.00
Compound Leverage Factor		 0.98 1.03 1.16 1.21 1.23 1.39 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 200.03% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -100.03% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 14.23 7.47 8.68 7.42 16.64 0.24 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 48.65% 200.03% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 14.20 13.06 10.65 9.77 9.63 3.11 0.00
Quick Ratio		 13.97 12.89 10.48 9.66 9.48 3.05 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 -485 -274 -196 -123 -82 -68 0.00
Operating Cash Flow to CapEx		 -5,407.80% -4,535.80% -2,074.71% -2,254.60% -3,411.66% -2,073.38% 80.92%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -1,149.94 -638.31 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -1,409.35 -468.08 10.46
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,450.66 -490.65 -2.47
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.01 0.05 0.05 0.11 0.23 0.00
Accounts Receivable Turnover		 0.00 3.91 6.67 4.77 5.68 5.73 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.56 2.34 2.87 5.36 7.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 93.41 54.69 76.51 64.24 63.73 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 93.41 54.69 76.51 64.24 63.73 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -24 -27 40 26 34 30 0.00
Invested Capital Turnover		 0.00 1.72 1.08 0.99 1.35 3.36 0.00
Increase / (Decrease) in Invested Capital		 2.67 -67 15 -8.42 4.16 30 0.00
Enterprise Value (EV)		 5,069 1,289 1,470 1,278 2,187 332 0.00
Market Capitalization		 7,358 3,142 2,115 1,855 2,628 150 150
Book Value per Share		 $13.47 $16.67 $7.72 $8.18 $7.15 ($55.03) $0.00
Tangible Book Value per Share		 $13.04 $16.01 $6.89 $7.17 $6.01 ($82.66) $0.00
Total Capital		 2,265 1,826 685 603 475 153 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2,289 -1,853 -645 -577 -441 -123 0.00
Capital Expenditures (CapEx)		 10 7.73 11 6.53 2.93 2.39 1.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -126 -118 -47 -48 -34 -32 0.00
Debt-free Net Working Capital (DFNWC)		 2,164 1,735 598 529 407 91 0.00
Net Working Capital (NWC)		 2,164 1,735 598 529 407 91 0.00
Net Nonoperating Expense (NNE)		 117 95 68 55 31 9.78 14
Net Nonoperating Obligations (NNO)		 -2,289 -1,853 -645 -577 -441 -123 0.00
Total Depreciation and Amortization (D&A)		 -33 -18 6.58 10 7.51 2.89 1.76
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,014.90% -132.11% -162.07% -78.62% -63.61% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 14,986.44% 1,690.79% 1,801.37% 946.76% 181.71% 0.00%
Net Working Capital to Revenue		 0.00% 14,986.44% 1,690.79% 1,801.37% 946.76% 181.71% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($3.58) ($3.86) ($3.08) ($2.57) ($2.01) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 167.74M 113.15M 80.63M 74.19M 73.38M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($3.58) ($3.86) ($3.08) ($2.57) ($2.01) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 167.74M 113.15M 80.63M 74.19M 73.38M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.57) ($2.01) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 185.91M 164.69M 90.49M 72.81M 54.87M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -483 -341 -181 -132 -77 -38 -28
Normalized NOPAT Margin		 0.00% -2,944.99% -511.01% -447.79% -180.28% -75.71% -140.00%
Pre Tax Income Margin		 0.00% -3,798.71% -704.14% -636.58% -252.50% -103.99% -207.24%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -1,559.11 -510.57 -365.95
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -1,091.38 -357.40 -243.36
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,600.42 -533.14 -378.87
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,132.69 -379.97 -256.29
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% -100.00% -94.62% -100.00% -58.05% -23.06% 45.79% 204.81%
EBITDA Growth		 -60.55% -21.51% -44.28% -45.54% -99.79% -225.38% -67.75% -87.31% -28.82% -15.22% -48.98%
EBIT Growth		 -70.53% -23.29% -42.34% -42.21% -85.96% -212.97% -61.04% -75.23% -21.05% -8.80% -43.96%
NOPAT Growth		 -70.92% -20.18% -42.57% -43.98% -87.42% -212.64% -61.04% -75.23% -21.05% -8.80% -43.96%
Net Income Growth		 -83.97% -20.45% -44.13% -35.54% -70.35% -205.18% -47.87% -60.56% -11.23% -0.49% -38.51%
EPS Growth		 -61.43% 8.13% 5.05% 11.96% 2.78% -115.79% -13.79% -12.20% 12.20% 20.83% -20.83%
Operating Cash Flow Growth		 -21.10% -14.70% -29.77% -90.95% -157.34% -95.12% -94.25% -20.47% -13.11% -57.36% -41.40%
Free Cash Flow Firm Growth		 -23.09% -161.24% -37.36% -255.57% -137.75% -7.18% -66.83% 8.15% -20.17% -92.29% -81.19%
Invested Capital Growth		 -211.85% 9.96% -30.66% 0.00% 2.72% -166.50% -8.12% 0.00% -33.79% 57.74% -10.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00% -45.48% -49.14% 310.97% -63.19%
EBITDA Q/Q Growth		 -7.41% -24.94% -11.87% -6.95% 18.04% -48.35% -12.85% -46.82% -32.38% 23.52% -26.01%
EBIT Q/Q Growth		 -7.29% -26.63% -13.39% -10.70% 22.35% -46.19% -13.28% -44.76% -30.55% 24.78% -23.26%
NOPAT Q/Q Growth		 -11.30% -23.10% -12.17% -11.21% 21.74% -46.03% -13.28% -44.76% -30.55% 24.78% -23.26%
Net Income Q/Q Growth		 -9.69% -24.49% -17.30% -14.85% 28.19% -48.97% -10.31% -44.35% -28.65% 27.82% -19.78%
EPS Q/Q Growth		 0.00% -20.21% -16.05% -15.71% 43.09% -24.24% -7.61% -27.78% -26.32% 34.48% -6.10%
Operating Cash Flow Q/Q Growth		 -40.60% -6.04% -1.76% 20.18% -33.18% -19.97% -49.73% -7.58% -0.98% -19.43% 7.14%
Free Cash Flow Firm Q/Q Growth		 20.77% -33.34% 16.13% -38.92% -68.16% 29.89% -117.11% 7.11% 24.19% -9.12% -19.54%
Invested Capital Q/Q Growth		 -1.78% -243.23% -40.20% 28.30% 181.94% -210.30% 0.00% -100.00% -46.96% 52.41% -29.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -25,241.64% 0.00% -2,925.60% -1,086.41% -417.35% -2,242.58%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -24,256.47% 0.00% -2,845.11% -1,071.53% -417.40% -2,280.48%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -24,281.81% 0.00% -2,845.11% -1,071.53% -417.40% -2,280.48%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -21,770.49% 0.00% -2,570.55% -970.89% -383.79% -2,185.01%
Tax Burden Percent		 100.00% 99.61% 100.00% 100.00% 100.00% 100.21% 96.56% 100.00% 100.00% 99.77% 99.60%
Interest Burden Percent		 89.55% 87.93% 89.09% 86.11% 83.00% 89.47% 91.12% 90.35% 90.61% 92.16% 96.20%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -29,163.89% 0.00% 0.00% -931.63% -314.40% -1,771.53%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -29,161.04% 0.00% 0.00% -929.47% -312.33% -1,768.41%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 29,004.47% 0.00% 0.00% 895.86% 296.38% 1,693.42%
Return on Equity (ROE)		 -36.68% -29.33% 0.00% 0.00% 0.00% -159.42% 0.00% 0.00% -35.78% -18.02% -78.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -2,189.54% -3,189.47% -1,791.43% 0.00% -999.41% 0.00% -668.28% -594.68% -623.34%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -195.70% 0.00% 0.00% -40.60% -19.06% -90.72%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -175.46% 0.00% 0.00% -36.79% -17.52% -86.93%
Return on Common Equity (ROCE)		 -36.68% -29.33% 0.00% 0.00% 0.00% -159.42% 0.00% 0.00% -35.78% -18.02% -78.11%
Return on Equity Simple (ROE_SIMPLE)		 -33.56% 0.00% -36.20% -32.07% -28.07% 0.00% -39.14% 0.00% -27.46% 0.00% -36.46%
Net Operating Profit after Tax (NOPAT)		 -169 -151 -123 -110 -99 -126 -86 -76 -53 -40 -54
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -16,979.53% 0.00% -1,991.58% -750.07% -292.18% -1,596.34%
Net Nonoperating Expense Percent (NNEP)		 -2.36% -2.08% -2.82% -2.97% -1.33% -2.85% -3.02% 0.00% -2.17% -2.07% -3.13%
Return On Investment Capital (ROIC_SIMPLE)		 -8.11% -6.68% - - - -6.90% - - - -5.88% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 4,345.55% 0.00% 382.85% 188.54% 70.65% 310.91%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 20,010.92% 0.00% 2,562.26% 982.99% 446.75% 2,069.58%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 24,356.47% 0.00% 2,945.11% 1,171.53% 517.40% 2,380.48%
Earnings before Interest and Taxes (EBIT)		 -238 -222 -175 -155 -140 -180 -123 -109 -75 -58 -77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -244 -228 -182 -163 -152 -187 -126 -112 -76 -58 -75
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.16 3.25 4.84 3.96 2.05 1.72 3.61 0.00 2.11 3.09 2.54
Price to Tangible Book Value (P/TBV)		 3.28 3.35 5.07 4.14 2.14 1.79 3.95 0.00 2.28 3.46 2.85
Price to Revenue (P/Rev)		 0.00 0.00 10,209.19 8,629.54 773.38 271.36 122.69 101.62 58.90 59.78 55.70
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 358.18 171.06 83.36 0.00 91.03 0.00 49.22 36.53 40.69
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 8,120.94 6,485.71 400.29 111.34 89.67 0.00 31.57 41.55 34.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -0.98 -0.98 -0.98 -0.99 -0.97 0.00 -0.96 -0.95 -0.96
Leverage Ratio		 1.12 1.13 1.14 1.12 1.12 1.14 1.19 0.00 1.19 1.20 1.18
Compound Leverage Factor		 1.01 0.99 1.02 0.96 0.93 1.02 1.09 0.00 1.07 1.11 1.14
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.25 14.84 22.55 19.92 11.45 7.96 11.48 0.00 7.84 9.50 6.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.46 14.20 14.24 15.42 18.45 13.06 9.64 0.00 11.81 10.65 9.21
Quick Ratio		 13.26 13.97 13.98 15.10 18.18 12.89 9.51 0.00 11.68 10.48 9.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -122 -154 -116 -138 -99 -59 -84 -39 -42 -55 -50
Operating Cash Flow to CapEx		 -5,953.31% -11,316.69% -3,705.09% -5,342.52% -5,069.78% -5,203.41% -3,964.38% -5,998.30% -3,548.98% -2,148.40% -1,467.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.00 0.04 0.05 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 3.91 9.38 0.00 8.43 6.67 5.03
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.03 0.03 0.21 0.56 1.28 0.00 2.03 2.34 2.19
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 93.41 38.89 0.00 43.29 54.69 72.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 93.41 38.89 0.00 43.29 54.69 72.61
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -25 -24 17 28 22 -27 24 0.00 21 40 26
Invested Capital Turnover		 0.00 0.00 0.04 0.05 0.21 1.72 0.97 0.00 1.24 1.08 1.11
Increase / (Decrease) in Invested Capital		 -46 2.67 -7.44 28 0.58 -67 -2.14 -37 -11 15 -3.14
Enterprise Value (EV)		 4,471 5,069 6,026 4,812 1,828 1,289 2,209 0.00 1,051 1,470 1,074
Market Capitalization		 6,574 7,358 7,575 6,403 3,531 3,142 3,022 2,844 1,960 2,115 1,729
Book Value per Share		 $11.18 $13.47 $9.38 $9.81 $10.47 $16.67 $7.67 $0.00 $10.29 $7.72 $7.77
Tangible Book Value per Share		 $10.80 $13.04 $8.95 $9.38 $10.04 $16.01 $7.01 $0.00 $9.48 $6.89 $6.93
Total Capital		 2,078 2,265 1,566 1,619 1,725 1,826 837 0.00 931 685 681
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2,103 -2,289 -1,549 -1,591 -1,704 -1,853 -813 0.00 -909 -645 -655
Capital Expenditures (CapEx)		 3.27 1.22 3.52 2.40 3.17 2.32 2.54 1.12 1.76 2.88 3.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -127 -126 -81 -71 -68 -118 -74 0.00 -65 -47 -53
Debt-free Net Working Capital (DFNWC)		 1,976 2,164 1,468 1,519 1,635 1,735 739 0.00 844 598 602
Net Working Capital (NWC)		 1,976 2,164 1,468 1,519 1,635 1,735 739 0.00 844 598 602
Net Nonoperating Expense (NNE)		 45 43 33 24 17 36 22 22 15 13 20
Net Nonoperating Obligations (NNO)		 -2,103 -2,289 -1,549 -1,591 -1,704 -1,853 -813 0.00 -909 -645 -655
Total Depreciation and Amortization (D&A)		 -6.10 -5.44 -6.72 -8.11 -12 -7.12 -3.00 -3.08 -1.04 0.01 1.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -10,944.07% -9,611.46% -1,490.60% -1,014.90% -301.54% 0.00% -196.69% -132.11% -171.27%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 197,880.86% 204,770.62% 35,818.64% 14,986.44% 3,000.11% 0.00% 2,536.31% 1,690.79% 1,938.41%
Net Working Capital to Revenue		 0.00% 0.00% 197,880.86% 204,770.62% 35,818.64% 14,986.44% 3,000.11% 0.00% 2,536.31% 1,690.79% 1,938.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.13) ($1.13) ($0.94) ($0.81) ($0.70) ($1.23) ($0.99) $0.00 $0.00 ($0.57) ($0.87)
Adjusted Weighted Average Basic Shares Outstanding		 188.15M 167.74M 166.84M 165.14M 164.73M 113.15M 109.23M 0.00 0.00 80.63M 84.69M
Adjusted Diluted Earnings per Share		 ($1.13) ($1.13) ($0.94) ($0.81) ($0.70) ($1.23) ($0.99) $0.00 $0.00 ($0.57) ($0.87)
Adjusted Weighted Average Diluted Shares Outstanding		 188.15M 167.74M 166.84M 165.14M 164.73M 113.15M 109.23M 0.00 0.00 80.63M 84.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 186.27M 185.91M 168.22M 167.04M 164.99M 164.69M 109.56M 0.00 0.00 90.49M 88.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -169 -151 -123 -110 -99 -126 -86 -76 -53 -40 -54
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -16,979.53% 0.00% -1,991.58% -750.07% -292.18% -1,596.34%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -21,724.26% 0.00% -2,570.55% -970.89% -384.68% -2,193.86%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Revolution Medicines' Financials

When does Revolution Medicines's financial year end?

According to the most recent income statement we have on file, Revolution Medicines' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Revolution Medicines' net income changed over the last 6 years?

Revolution Medicines' net income appears to be on an upward trend, with a most recent value of -$600.09 million in 2024, rising from -$41.79 million in 2018. The previous period was -$436.37 million in 2023. View Revolution Medicines' forecast to see where analysts expect Revolution Medicines to go next.

What is Revolution Medicines's operating income?
Revolution Medicines's total operating income in 2024 was -$689.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $689.52 million
How has Revolution Medicines revenue changed over the last 6 years?

Over the last 6 years, Revolution Medicines' total revenue changed from $20.17 million in 2018 to $0.00 in 2024, a change of -100.0%.

How much debt does Revolution Medicines have?

Revolution Medicines' total liabilities were at $293.10 million at the end of 2024, a 24.5% increase from 2023, and a 331.1% increase since 2019.

How much cash does Revolution Medicines have?

In the past 5 years, Revolution Medicines' cash and equivalents has ranged from $16.66 million in 2019 to $696.15 million in 2023, and is currently $543.06 million as of their latest financial filing in 2024.

How has Revolution Medicines' book value per share changed over the last 6 years?

Over the last 6 years, Revolution Medicines' book value per share changed from 0.00 in 2018 to 13.47 in 2024, a change of 1,346.6%.


Related Companies

This page (NASDAQ:RVMD) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored